← Back to directory

Stefan Laufer

Researcher Next ID · RN-039921

Researcher · Biochemistry, Genetics and Molecular Biology

Acoustics Research Institute

Vienna, Austria

Accepting doctoral researchersFunding unknown
Works count
790
Citation count
19,804
H-index
70
i10-index
322

Research interests

Biochemistry, Genetics and Molecular Biology
Chemistry
Computer Science
Materials Science
Melanoma and MAPK Pathways
Synthesis and biological activity
Crystallization and Solubility Studies
X-ray Diffraction in Crystallography
Computational Drug Discovery Methods

Publications

  • Candidate drugs against SARS-CoV-2 and COVID-19

    Pharmacological Research · 2020 · https://doi.org/10.1016/j.phrs.2020.104859

  • Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology

    Journal of Medicinal Chemistry · 2018 · https://doi.org/10.1021/acs.jmedchem.8b01153

  • Progress towards a public chemogenomic set for protein kinases and a call for contributions

    PLoS ONE · 2017 · 10.1371/journal.pone.0181585

  • The Cysteinome of Protein Kinases as a Target in Drug Development

    Angewandte Chemie International Edition · 2017 · 10.1002/anie.201707875

  • Proteasome Activation by Small Molecules

    Cell chemical biology · 2017 · 10.1016/j.chembiol.2017.05.010

  • IL‐1β, IL‐18, and eicosanoids promote neutrophil recruitment to pore‐induced intracellular traps following pyroptosis

    European Journal of Immunology · 2016 · 10.1002/eji.201646647

  • A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer

    Nature Medicine · 2016 · 10.1038/nm.4107

  • Spinal inhibition of p38 MAP kinase reduces inflammatory and neuropathic pain in male but not female mice: Sex-dependent microglial signaling in the spinal cord

    Brain Behavior and Immunity · 2015 · 10.1016/j.bbi.2015.10.006

  • In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer

    Nature Medicine · 2014 · https://doi.org/10.1038/nm.3679

  • Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors

    European Journal of Medicinal Chemistry · 2013 · 10.1016/j.ejmech.2013.10.058

  • Skepinone-L, a Novel Potent and Highly Selective Inhibitor of p38 MAP Kinase, Effectively Impairs Platelet Activation and Thrombus Formation

    Cellular Physiology and Biochemistry · 2013 · https://doi.org/10.1159/000350110

  • Biological studies on Brazilian plants used in wound healing

    Journal of Ethnopharmacology · 2009 · 10.1016/j.jep.2009.01.022

  • Determination of the wound healing effect of Calendula extracts using the scratch assay with 3T3 fibroblasts

    Journal of Ethnopharmacology · 2009 · https://doi.org/10.1016/j.jep.2009.09.014

  • Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI

    Annals of the Rheumatic Diseases · 2008 · 10.1136/ard.2008.088732

  • Licofelone Suppresses Prostaglandin E2 Formation by Interference with the Inducible Microsomal Prostaglandin E2 Synthase-1

    Journal of Pharmacology and Experimental Therapeutics · 2008 · 10.1124/jpet.108.139444

  • Tetrasubstituted Imidazole Inhibitors of Cytokine Release: Probing Substituents in the N-1 Position

    Journal of Medicinal Chemistry · 2004 · 10.1021/jm0496584

  • The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K

    Bone · 2003 · 10.1016/j.bone.2003.11.021

  • Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept

    Pharmacological Research · 2001 · 10.1006/phrs.2000.0784

  • Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease

    Journal of Neural Transmission · 1998 · https://doi.org/10.1007/s007020050068

Current projects

    No projects listed.